The global plasmid purification market size is anticipated to reach USD 3.69 billion by 2030 and is projected to grow at a CAGR of 11.60% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising acceptance of cell & gene therapy and growing demand for recombinant technology products are factors contributing to market growth. Moreover, technological advancements in plasmid purification further propel market growth.
Plasmids are crucial in gene therapy and genetic medicine. Their unique properties allow them to serve as effective vectors for delivering therapeutic genes into target cells. Plasmids function by introducing exogenous genes into specific cells to correct or replace defective genes responsible for diseases. Moreover, with the increasing acceptance and application of gene therapy for treating various diseases, there is a growing need for purified plasmid DNA. In gene therapy, plasmids serve as vectors for delivering therapeutic genes.
Researchers design plasmids to carry therapeutic genes, including normal copies of mutated genes, genes encoding proteins to combat disease, or RNA molecules like shRNA that can silence harmful genes. Plasmid purification is critical in the development and application of gene therapy. Contaminants such as chromosomal DNA, proteins, endotoxins, and residual bacterial components can interfere with the efficacy and safety of the therapeutic product. Thus, advancements in purification technologies enhance the yield and quality of plasmid DNA, facilitating the scalability of plasmid production, which is essential for meeting the increasing demands of gene therapy development.
The COVID-19 pandemic has significantly impacted the market growth. The increased demand for synthetic biology products, driven by the urgent need for COVID-19 vaccines and treatments, has accelerated research and development (R&D) in cloning technology. This surge in R&D activities in synthetic biology has led to increased funding and investment in companies involved in vaccine development, diagnostics, and therapeutic research. Moreover, despite the challenges posed by the pandemic, the market is expected to continue growing steadily due to the increasing adoption of novel technologies, the rising demand for gene therapies, and ongoing advancements in genetic engineering.
However, one of the primary concerns of the market is the ethical constraints related to the use of recombinant DNA technology is the misuse of gene cloning and synthesis technology in the creation of harmful pathogens through synthetic biology techniques to develop bioweapons. Improper handling or disposal of synthetic DNA and plasmids could lead to environmental contamination. Engineered organisms released into the environment could have ecological consequences.
Request a free sample copy or view report summary: Plasmid Purification Market Report
The products segment led the market with the largest revenue share of 72.93% in 2023, as the use of specialized kits and reagents significantly enhances the efficiency, reliability, and quality of the purification process. Furthermore, the services segment is anticipated to experience at a significant CAGR of 12.58% from 2024 to 2030
Based on grade, the molecular grade segment led the market with the largest revenue share of 58.42% in 2023, as these plasmids are engineered to be easily manipulated and modified, allowing researchers to make precise changes to the genetic material. The transfection grade segment is anticipated to grow at the fastest CAGR of 13.24% over the forecast period
Based on application, the cloning & protein segment led the market with the largest revenue share of 48.76% in 2023, owing to the growing demand for genetically modified crops and organisms. Furthermore, the transfection & gene editing segment is expected to grow at the fastest CAGR over the forecast period.
Based on end use, the academic & research institutes segment led the market with the largest revenue share of 40.12% in 2023, driven by their significant contribution to R&D to bring novel gene therapy treatments and engineered biotechnological products to market. Also, the contract research organizations segment is expected to expand at the fastest CAGR of 13.38% during the forecast period, due to their increasing adoption and investment in advanced research and manufacturing technologies
North America dominated the market with the largest revenue share of 40.58% in 2023, owing to factors such as increasing investments in R&D activities, rising demand for personalized medicine, and advanced biotechnology research infrastructure
Grand View Research has segmented the global plasmid purification market based on product & service, grade, application, end-use, and region:
Plasmid Purification Product & Service Outlook (Revenue, USD Million, 2018 - 2030)
Products
Instruments
Kits & Reagents
Services
Plasmid Purification Grade Outlook (Revenue, USD Million, 2018 - 2030)
Molecular Grade
Transfection Grade
Plasmid Purification Application Outlook (Revenue, USD Million, 2018 - 2030)
Cloning & Protein Expression
Transfection & Gene Editing
Others
Plasmid Purification End Use Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical & Biotechnology Companies
Academic & Research Institutes
Contract Research Organizations
Plasmid Purification Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
MEA
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Plasmid Purification Market
Merck KGaA
QIAGEN
Thermo Fisher Scientific, Inc.
Takara Bio
Promega Corporation
Zymo Research
MP BIOMEDICALS
New England Biolabs
MCLAB
Applied Biological Materials Inc.
"The quality of research they have done for us has been excellent..."